NEW YORK, April 4, 2017 /PRNewswire/ --
Companies in the Medical Appliances and Equipment space are engaged in the manufacture of medical instruments such as dental and surgical appliances. They also tend to offer below-average dividend yields when compared to the wider market. Today, Stock-Callers.com monitors the following four equities: Varex Imaging Corp. (NASDAQ: VREX), Masimo Corp. (NASDAQ: MASI), Varian Medical Systems Inc. (NYSE: VAR), and Xtant Medical Holdings Inc. (NYSE MKT: XTNT). Learn more about these stocks by downloading their free report at:
On Monday, shares in Salt Lake City, Utah headquartered Varex Imaging Corp. recorded a trading volume of 227,132 shares. The stock ended the session 1.19% lower at $33.20. The Company's shares have gained 0.15% in the last one month and 22.96% on an YTD basis. The stock is trading 6.60% above its 50-day moving averages. Moreover, shares of Varex Imaging, which designs and manufactures medical X-ray tubes and image processing solutions, have a Relative Strength Index (RSI) of 61.72.
On March 22nd, 2017, Varex Imaging announced that it has entered into a renewed three-year pricing agreement with Toshiba Medical Systems under which Varex Imaging will continue to supply its computed tomography (CT) tubes for integration into Toshiba Medical's CT imaging systems for the global market. Potential sales of CT tubes associated with this renewed agreement are estimated to be in the range of $345 million to $385 million. The free research report on VREX is available at:
Irvine, California headquartered Masimo Corp.'s stock closed the day 0.12% lower at $93.15. A total volume of 948,414 shares was traded, which was above their three months average volume of 840,040 shares. The Company's shares have advanced 38.20% in the previous three months. The stock is trading 9.19% and 41.65% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Masimo, which develops, manufactures, and markets noninvasive monitoring technologies worldwide, have an RSI of 62.76.
On March 16th, 2017, research firm Piper Jaffray downgraded the Company's stock rating from 'Overweight' to 'Neutral'.
On March 27th, 2017, Masimo announced that Massena Memorial Hospital of Massena, New York, has adopted Masimo Root® and Patient SafetyNet™. The hospital is integrating Root with wearable rainbow SET™ Pulse CO-Oximeter® Radius-7® and Patient SafetyNet to implement a wireless monitoring, patient data automation, and supplemental remote clinician notification system that will be used in all medical-surgical units. The complimentary report on MASI can be downloaded at:
Shares in Varian Medical Systems Inc. recorded a trading volume of 1.02 million shares, which was above their three months average volume of 949,660 shares. The stock ended yesterday's trading session 0.40% higher at $91.49. The Company's shares have advanced 5.26% in the past month, and 1.90% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 6.59% and 1.50%, respectively. Furthermore, shares of Varian Medical Systems, which designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions worldwide, have an RSI of 74.47.
On March 29th, 2017, Varian Medical Systems announced that it will report results for Q2 FY17 following the close of regular trading on Wednesday, April 26th, 2017. The news release will be followed by a teleconference available to all interested parties at 2:00 p.m. PT. The news release and a link to the conference call webcast will be available on the Company's website. Visit us today and download our complete research report on VAR for free at:
Belgrade, Montana headquartered Xtant Medical Holdings Inc.'s stock finished Monday's session 0.34% higher at $0.63, with a total trading volume of 299,730 shares. The Company's shares have advanced 22.55% in the last one month, and 13.64% since the start of this year. The stock is trading above its 50-day moving average by 24.66%. Additionally, shares of Xtant Medical Holdings, which develops, manufactures, and markets regenerative medicine products and devices in the US and internationally, have an RSI of 54.95.
On March 09th, 2017, Xtant Medical Holdings reported its financial results for the period ended December 31st, 2016. Consolidated revenue was approximately $24.5 million and $90.0 million for Q4 2016 and full-year 2016, respectively. Q4 2016 consolidated net loss was $4.5 million, and full-year 2016 net loss was $19.5 million. Get free access to your technical report on XTNT at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA